1. Home
  2. ARQT vs FPF Comparison

ARQT vs FPF Comparison

Compare ARQT & FPF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Arcutis Biotherapeutics Inc.

ARQT

Arcutis Biotherapeutics Inc.

HOLD

Current Price

$28.33

Market Cap

3.3B

Sector

Health Care

ML Signal

HOLD

Logo First Trust Intermediate Duration Preferred & Income Fund of Beneficial Interest

FPF

First Trust Intermediate Duration Preferred & Income Fund of Beneficial Interest

HOLD

Current Price

$18.60

Market Cap

1.1B

Sector

Finance

ML Signal

HOLD

Company Overview

Basic Information
Metric
ARQT
FPF
Founded
2016
2013
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Trusts Except Educational Religious and Charitable
Sector
Health Care
Finance
Exchange
Nasdaq
Nasdaq
Market Cap
3.3B
1.1B
IPO Year
2020
N/A

Fundamental Metrics

Financial Performance
Metric
ARQT
FPF
Price
$28.33
$18.60
Analyst Decision
Strong Buy
Analyst Count
7
0
Target Price
$24.83
N/A
AVG Volume (30 Days)
2.0M
186.7K
Earning Date
10-28-2025
01-01-0001
Dividend Yield
N/A
8.08%
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$317,929,000.00
N/A
Revenue This Year
$85.51
N/A
Revenue Next Year
$30.74
N/A
P/E Ratio
N/A
N/A
Revenue Growth
129.21
N/A
52 Week Low
$11.13
$13.91
52 Week High
$31.77
$18.09

Technical Indicators

Market Signals
Indicator
ARQT
FPF
Relative Strength Index (RSI) 51.18 50.60
Support Level $27.55 $18.40
Resistance Level $28.90 $18.63
Average True Range (ATR) 1.15 0.13
MACD -0.54 0.02
Stochastic Oscillator 18.82 86.64

Price Performance

Historical Comparison
ARQT
FPF

About ARQT Arcutis Biotherapeutics Inc.

Arcutis Biotherapeutics Inc is a medical dermatology company. It is developing treatments for patients with immune-mediated dermatological diseases and conditions. It is leveraging recent advances in immunology and inflammation to develop differentiated therapies against biologically validated targets to solve persistent treatment challenges in serious diseases of the skin. The company's product candidate ZORYVE roflumilast cream, has completed pivotal Phase 3 clinical trials in plaque psoriasis, demonstrating symptomatic improvement and favorable tolerability in this population.

About FPF First Trust Intermediate Duration Preferred & Income Fund of Beneficial Interest

First Trust Inter Dur Pref& Income Fund is a diversified, closed-end management investment company. Its primary investment objective is to seek a high level of current income. Further, it has a secondary objective of capital appreciation. The Fund invests in the traditional preferred securities, hybrid preferred securities, floating rate & fixed-to-floating rate preferred securities, debt securities, convertible securities, and contingent convertible securities issued by U.S. and non-U.S. companies. Its investment portfolio includes industries such as Banks, Insurance, Capital Markets, Electric Utilities, Oil, Gas & Consumable Fuels, Food Products, and others.

Share on Social Networks: